Literature DB >> 26989361

Role of Hyperthermia in Breast Cancer Locoregional Recurrence: A Review.

Sergio Maluta1, Merel Willemijn Kolff2.   

Abstract

In patients with locoregional recurrences of breast cancer not suitable for resection, subsequent local control is difficult to maintain in previously irradiated areas when reirradiation alone or reirradiation with chemotherapy is used. Due to the limited number of treatment options there is a high risk of subsequent failure and uncontrollable local disease. In this group of patients, local hyperthermia combined with radiotherapy increases the clinical response and local control, adding limited acute and late toxicity, as has been shown in randomized trials. Hyperthermia is an artificial elevation of tissue temperature (range 40-44°C for 30-60 min). If hyperthermia is applied shortly before or after radiation, the effect of radiation is enhanced by influencing intratumoral hypoxia and by inhibiting sublethal damage repair in the tumor. Moreover, hyperthermia combined with radiation reduces the total dose of radiation needed compared to radiation alone, of which a higher dose is needed to obtain the same effect. Few data are available on the combination of radiotherapy and hyperthermia with chemotherapy, although the results of trimodality treatment consisting of reirradiation and hyperthermia together with liposomal doxorubicin are promising. Therefore, this literature review was performed to provide more comprehensive data on the mechanism and use of hyperthermia in locoregional recurrence of breast cancer.

Entities:  

Keywords:  Breast cancer; Hyperthermia; Recurrence

Year:  2015        PMID: 26989361      PMCID: PMC4789878          DOI: 10.1159/000440792

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  44 in total

Review 1.  Hyperthermic isolation limb perfusion for malignant melanoma: a review.

Authors:  D G Coit
Journal:  Cancer Invest       Date:  1992       Impact factor: 2.176

2.  A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma.

Authors:  Y Harima; K Nagata; K Harima; V V Ostapenko; Y Tanaka; S Sawada
Journal:  Int J Hyperthermia       Date:  2001 Mar-Apr       Impact factor: 3.914

3.  Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group.

Authors:  J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

4.  Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme.

Authors:  P K Sneed; P R Stauffer; M W McDermott; C J Diederich; K R Lamborn; M D Prados; S Chang; K A Weaver; L Spry; M K Malec; S A Lamb; B Voss; R L Davis; W M Wara; D A Larson; T L Phillips; P H Gutin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-15       Impact factor: 7.038

Review 5.  Hyperthermia in oncology.

Authors:  M H Falk; R D Issels
Journal:  Int J Hyperthermia       Date:  2001 Jan-Feb       Impact factor: 3.914

Review 6.  Heating the patient: a promising approach?

Authors:  J van der Zee
Journal:  Ann Oncol       Date:  2002-08       Impact factor: 32.976

7.  Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology.

Authors:  J Overgaard; D Gonzalez Gonzalez; M C Hulshof; G Arcangeli; O Dahl; O Mella; S M Bentzen
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

Review 8.  Locally advanced noninflammatory breast cancer.

Authors:  K K Hunt; F C Ames; S E Singletary; A U Buzdar; G N Hortobagyi
Journal:  Surg Clin North Am       Date:  1996-04       Impact factor: 2.741

9.  Hyperthermia in cancer: is it coming of age?

Authors:  Adam Januszewski; Justin Stebbing
Journal:  Lancet Oncol       Date:  2014-05       Impact factor: 41.316

10.  Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.

Authors:  Timothy M Zagar; Zeljko Vujaskovic; Silvia Formenti; Hope Rugo; Franco Muggia; Brigid O'Connor; Robert Myerson; Paul Stauffer; I-Chow Hsu; Chris Diederich; William Straube; Mary-Keara Boss; Alina Boico; Oana Craciunescu; Paolo Maccarini; David Needham; Nicholas Borys; Kimberly L Blackwell; Mark W Dewhirst
Journal:  Int J Hyperthermia       Date:  2014-08       Impact factor: 3.914

View more
  4 in total

1.  Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy.

Authors:  Michael Hader; Deniz Pinar Savcigil; Andreas Rosin; Philipp Ponfick; Stephan Gekle; Martin Wadepohl; Sander Bekeschus; Rainer Fietkau; Benjamin Frey; Eberhard Schlücker; Udo S Gaipl
Journal:  Cancers (Basel)       Date:  2020-04-27       Impact factor: 6.639

2.  Heat shock response regulates stimulus-specificity and sensitivity of the pro-inflammatory NF-κB signalling.

Authors:  Anna Paszek; Małgorzata Kardyńska; James Bagnall; Jarosław Śmieja; David G Spiller; Piotr Widłak; Marek Kimmel; Wieslawa Widlak; Pawel Paszek
Journal:  Cell Commun Signal       Date:  2020-05-24       Impact factor: 5.712

3.  The Influence of Cold Atmospheric Pressure Plasma-Treated Media on the Cell Viability, Motility, and Induction of Apoptosis in Human Non-Metastatic (MCF7) and Metastatic (MDA-MB-231) Breast Cancer Cell Lines.

Authors:  Dominik Terefinko; Anna Dzimitrowicz; Aleksandra Bielawska-Pohl; Aleksandra Klimczak; Pawel Pohl; Piotr Jamroz
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

4.  Cell mechanical properties of human breast carcinoma cells depend on temperature.

Authors:  Christian Aermes; Alexander Hayn; Tony Fischer; Claudia Tanja Mierke
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.